NCT01929044 - Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain | Biotech Hunter

Enrollment

299

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Intestinal Diseases

Interventions

DRUG

654-II (anisodamine)

10mg injection

DRUG

Buscopan® (hyoscine butylbromide)

20mg injection

Trial Locations (20)

202.848.86016 Boehringer Ingelheim Investigational Site, Baotou

202.848.86008 Boehringer Ingelheim Investigational Site, Beijing

202.848.86009 Boehringer Ingelheim Investigational Site, Beijing

202.848.86010 Boehringer Ingelheim Investigational Site, Beijing

202.848.86013 Boehringer Ingelheim Investigational Site, Beijing

202.848.86012 Boehringer Ingelheim Investigational Site, Changchun

202.848.86020 Boehringer Ingelheim Investigational Site, Changsha

202.848.86018 Boehringer Ingelheim Investigational Site, Chenzhou

202.848.86007 Boehringer Ingelheim Investigational Site, Chongqing

202.848.86021 Boehringer Ingelheim Investigational Site, Chongqing

202.848.86006 Boehringer Ingelheim Investigational Site, Guangzhou

202.848.86003 Boehringer Ingelheim Investigational Site, Hangzhou

202.848.86022 Boehringer Ingelheim Investigational Site, Huanggang

202.848.86001 Boehringer Ingelheim Investigational Site, Shanghai

202.848.86011 Boehringer Ingelheim Investigational Site, Shanghai

202.848.86015 Boehringer Ingelheim Investigational Site, Shenyang

202.848.86014 Boehringer Ingelheim Investigational Site, Shijiazhuang

202.848.86019 Boehringer Ingelheim Investigational Site, Wenzhou

202.848.86004 Boehringer Ingelheim Investigational Site, Wuhan

202.848.86005 Boehringer Ingelheim Investigational Site, Wuhan